This study suggested that decreased expressions of c-erbB-2 and CXCR4 may be a novel mechanism of chemotherapy; the changes of these objective markers may be useful in evaluating the clinical response of neo-adjuvant chemotherapy and selecting chemotherapy regimen for postoperative chemotherapy in breast cancer. The gene discussed is CXCR4; the disease is breast cancer.